<?xml version="1.0" encoding="UTF-8"?>
<p>The use of glucocorticoids in patients with SARS-CoV-2 infection, especially in those with severe disease, was a point of major controversy. The rationale behind their use is to decrease lung inflammation as seen in ARDS. However, this comes with adverse effects such as inhibiting the immune response and thus increasing the risk of secondary infections as well as delaying viral clearance (
 <xref rid="B107" ref-type="bibr">107</xref>). A Cochran review published in July 2019 that included 48 RCTs found insufficient evidence to determine if corticosteroids were effective at reducing mortality and duration of mechanical ventilation in patients with ARDS (
 <xref rid="B108" ref-type="bibr">108</xref>).
</p>
